Mitogen-activated protein kinase (MAPK) cascades are the central components of the intracellular signaling networks that eukaryotic cells use to respond to a wide spectrum of extracellular stimuli. MAPKs are activated through a module consisting of a MAPK, a MAPK kinase (MKK), and a MKK kinase (MAP3K). Because of its unique position in the MAPK module, a MAP3K is crucial in relaying the upstream receptor-mediated signals through the MAPK cascades to induce physiological responses. Yet, the underlying molecular mechanism of MAP3K regulation and activation remains largely unknown. In this study, we demonstrated that MAP3K MEKK2 activation requires dimerization. We mapped the MEKK2 dimerization motif in its catalytic domain and showed that the NH 2 -terminal region is not required for MEKK2 dimer formation. We also found that the inactive, non-phosphorylated MEKK2 formed significantly more dimers than the phosphorylated and, hence, active MEKK2. Moreover, prevention of MEKK2 dimer formation inhibited MEKK2-mediated JNK activation. Using a chemical-induced dimerization system, we further demonstrated that MEKK2 dimer formation in vivo augmented MEKK2-dependent JNK activation and JNK/AP-1 reporter gene transcription. Together, these results suggest a novel mechanism underlying MEKK2 regulation and activation.
Mitogen-activated protein kinase (MAPK) 1 cascades are essential intracellular signaling networks that eukaryotic cells use to transduce signals triggered by a wide spectrum of extracellular stimuli. Activation of a MAPK requires a MAPK kinase, which, in turn, is activated by a MAP3K. Whereas much has been learned about how a MAPK or a MAPK kinase is activated, the molecular mechanisms of MAP3K activation remain largely unknown in the mammalian system.
A growing number of MAP3Ks have been identified that are capable of activating the c-Jun NH 2 -terminal kinase (JNK) and p38 MAPKs, including MEKK1, MEKK3, MEKK4, MEKK5, apoptosis signal-regulating kinase 1, transforming growth factor-␤ (TGF-␤)-activated kinase 1, mixed lineage kinases, dual leucine zipper-bearing kinase, and Tpl2 (1) (2) (3) (4) (5) (6) (7) (8) . These MAP3Ks have in common a conserved catalytic domain with substantial homology to that of the yeast MAP3K STE11 (9) . There is increasing evidence from biochemical and genetic studies showing that the MAP3Ks are responsible for sorting distinct cell surface signals through various downstream MAPK pathways to the cytoplasmic and nuclear effectors. Genetic studies using gene-targeting mice revealed that members of the MAP3K family have both overlapping and distinct functions. For example, MEKK2 is involved in T-cell and mast cell function but not required for embryonic development (10, 11) . In contrast, MEKK3 is essential for early embryonic cardiovascular and neuronal development (12) . MEKK3 is also involved in signaling pathways downstream of the cytokine receptors and Toll-like receptors (13, 14) .
MEKK2 is a Ser/Thr protein kinase belonging to the MEKK/ STE11 subgroup of the MAP3K family (3, 15) . In vitro, MEKK2 activates JNK, extracellular signal-regulated kinase (ERK), p38, and ERK5/big MAPK (BMK) MAPKs (3, 11, 16 -18) . The strong and specific JNK activation by MEKK2 was mediated by the JNK-activating kinase JNKK2 through the formation of a tripartite molecular complex consisting of MEKK2, JNKK2, and JNK1 (18) . Activation of the ERK1/2, p38, and ERK5 MAPKs by MEKK2 was mediated by MEK1/2, MKK3/6, and MEK5, respectively (3, 16, 19) . In vivo, MEKK2 may negatively regulate T-cell function (10) . MEKK2 has also been shown to regulate cytokine gene expression in mast cells (11, 19) , mediate epidermal growth factor receptor and fibroblast growth factor-2 receptor signals (20, 21) , and play a role in rheumatoid arthritis (22) .
Despite extensive efforts in the past, it is still largely unknown how MEKK2, as well as other MAP3Ks, is activated. One major hurdle preventing us from understanding this process is that overexpression, common to transient transfections, constitutively activates most MAP3Ks in the absence of any agonist stimuli, leading toward the activation of downstream MAPKs such as the JNKs, ERKs, and p38. In this study we investigated the molecular mechanisms of MEKK2 activation. We found that MEKK2 forms dimers through its catalytic domain. The dimerization is essential for MEKK2 phosphorylation and activation.
MATERIALS AND METHODS
Cell Culture and Transient Transfection-COS-1 and 293T cells were cultured in Dulbecco's modified Eagle's medium, supplemented with 5% fetal bovine serum, 100 units/ml penicillin, and 100 mg/ml streptomycin. Plasmid DNA was transfected with Lipofectamine (Invitrogen).
Plasmids, Proteins, and Antibodies-FLAG-tagged JNK1, HA-tagged JNK2, MEKK2-(1-342), MEKK2-(342-619), MEKK2-(342-424), MEKK2-(1-619), MEKK2-(342-619)(KM), MEKK2-(1-619)(KM), and the glutathione S-transferase (GST)-tagged MEKK2 and MEKK2-(342-619) mammalian expression plasmids Gal4-luc and Gal4-c-Jun were described previously (12, 15, 18, 23, 24) . FvMEKK2CT and FvMEKK3CT were constructed by introducing a SalI site at codon 358 (Pro) and another SalI site before the stop codon (the SalI-SalI fragment contains amino acids 358 -619 of MEKK2) in MEKK2, as well as a XhoI site at codon 355 (Pro) and a SalI site before the stop codon (the XhoI-SalI fragment contains amino acids 355-626 of MEKK3) of MEKK3 by PCR-mediated mutagenesis. The PCR products were confirmed by DNA sequencing and subcloned into vector pSH1/S N -E-FvЈ-Fvls-E (25) at the SalI site to allow an in-frame fusion of the FKBP12V36 ("Fv") MEKK2-(342-619)(KM) domain from the vector with MEKK2 and MEKK3 catalytic domains, respectively. A diagram showing the different forms of the MEKK2 constructs used in this study is displayed in Fig. 1 . The GST-c-Jun recombinant protein was described previously (23) . The anti-HA antibody 12CA5 was prepared from a 12CA5 hybridoma and further purified using a protein A-Sepharose column. The anti-MEKK2 antibody 1128 was described previously (18) .
Immunoprecipitation, in Vitro Kinase Assay, and GST Pull-down Assay-Cell lysate preparation, immunoprecipitation, and in vitro kinase assays were performed as described in our previous studies (18, 23) . For the GST pull-down assay, COS-1 cells were transfected with HA-, FLAG-, or GST-tagged expression vectors and lysed 40 h after transfection using a low salt lysis buffer (50 mM HEPES, pH 7.6, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1% Triton X-100, and 10% glycerol). Nuclear and cellular debris were removed from the lysates by centrifugation for 20 min at 4°C. GST-fusion proteins were precipitated from the clarified lysates with GSH-Sepharose at 4°C for a 4-h incubation in a rotator. The beads were washed four times with a low salt lysis buffer, and the precipitated complexes were analyzed by immunoblotting with appropriate antibodies.
Luciferase Reporter Assay-For the Gal4-luciferase reporter gene assay, the reporter plasmid Gal4-Luc was co-transfected with empty vector or Gal4-cJun-(1-223) alone or with FvMEKKCT or FvMEKK3CT constructs. A ␤-actin-Renilla luciferase reporter vector was included in every experiment for transfection efficiency control. Relative luciferase activity was determined and normalized to Renilla luciferase activity.
Chemically Induced Dimerization-Synthetic dimerizer AP20187-mediated MEKK2 and MEKK3 dimer formation was carried out as described previously (26) .
RESULTS

MEKK2 Activation Requires Self-phosphorylation-Previ-
ously, we and others found that the transient expression of MEKK2 in various cell lines led to a strong activation of its downstream targets, including the JNK and p38 MAPKs (3, 15, 18) . These results suggest that MEKK2 may be capable of self-activation without the need for any upstream agonist stimulation. When transiently expressed, the full-length MEKK2 and its COOH-terminal catalytic domain (amino acids 342-619) (an active form of MEKK2) displayed multiple protein bands on SDS-PAGE gels (Fig. 2, A and B) . When treated with a protein phosphatase, the bands showing a slower mobility were significantly reduced, suggesting that MEKK2 is a phosphoprotein. In addition, when kinase-inactive forms of MEKK2, MEKK2(KM) ( Fig. 2A ) or MEKK2-(342-619)(KM) (Fig. 2B ), were expressed, only the faster migrating bands were observed, suggesting that they were non-phosphorylated or hypo-phosphorylated species. These results also indicate that MEKK2 phosphorylation may be dependent on its catalytic activity. Using an in vitro kinase assay, we further demonstrated that MEKK2-(342-619) was able to phosphorylate itself and also phosphorylate JNKK2, one of its major substrates (18) (Fig. 2C ). In contrast, neither MEKK2-(342-619)(KM) nor the protein phosphatase-treated MEKK2-(342-619) was able to phosphorylate JNKK2. Thus, these results strongly suggest that MEKK2 phosphorylation is required for its activation.
MEKK2 Forms Dimers through Its Catalytic Domain-Transient expression of the JNK1/2 or ERK1/2 MAPKs usually does not lead to their activation in contrast to MEKK2 expression. This suggests that the molecular mechanisms of MAPK activation may be fundamentally different from that of a MAP3K. Because one of the consequences of transient expression of MEKK2 is elevated intracellular MEKK2 concentration, it is possible that this increased MEKK2 concentration may activate itself through spontaneous dimerization. Dimer formation mediated by ligands or adaptor molecules has been shown to activate many receptor tyrosine kinases (27) (28) (29) and Ser/Thr 
FIG. 2. MEKK2 autophosphorylation is required for its activity.
A and B, MEKK2 is a phosphoprotein. HA-tagged MEKK2-(1-619), MEKK2-(1-619)(KM) (A), MEKK2-(342-619), and MEKK2-(342-619)(KM) (B) expressed in COS-1 cells were examined by immunoblotting with an anti-HA antibody. For calf intestine phosphatase (CIP) treatment, cell lysates were prepared in the absence of phosphatase inhibitors and incubated with 1 unit/ml CIP at 37°C for 30 min before immunoblotting analysis. NS, nonspecific band. C, dephosphorylation inactivates MEKK2. HA-tagged MEKK2-(342-619) and MEKK2-(342-619)(KM) were expressed as described for panel A and subjected to immunoprecipitation with an anti-HA antibody. The MEKK2-(342-619) immunocomplex was divided into two parts that were either untreated or treated with calf intestine phosphatase as described for panel A before being used in an in vitro kinase assay using JNKK2(KM) as a substrate. Phosphorylated MEKK2 (pMEKK2) and JNKK2 (pJNKK2) are indicated. The MEKK2 and JNKK2 protein levels were examined by immunoblotting (middle and bottom).
kinases, such as members of the transforming growth factor-␤ receptor family (30) and c-Raf-1 (29) .
To determine whether MEKK2 forms dimers, we co-expressed GST-fused MEKK2 (GST-MEKK2) with HA-tagged NH 2 -terminal (amino acids 1-342) or COOH-terminal (amino acids 342-619) regions of MEKK2 for a GST pull-down assay. As shown in Fig. 3A , the COOH-terminal catalytic domain, but not with the NH 2 -terminal region of MEKK2, was co-precipitated by the full-length MEKK2. This finding suggests that MEKK2 forms dimers through its catalytic domain. To confirm this hypothesis, we co-expressed a GST-fused catalytic domain of MEKK2, GST-MEKK2-(342-619), with the full-length MEKK2 and the NH 2 -terminal and COOH-terminal regions of MEKK2 or a truncated catalytic domain of MEKK2:MEKK2-(342-424). As expected, we found that the GST-MEKK2 (342-619) co-precipitated with the full-length and the COOH-terminal but not the NH 2 -terminal regions of MEKK2 (Fig. 3B) . Interestingly, we found that the truncated catalytic domain MEKK2-(342-424) was also co-precipitated with GST-MEKK2-(342-619), indicating that this region, which includes most of the kinase subdomains I-III of MEKK2, includes the dimerization domain for MEKK2.
If this assumption is correct, we would expect overexpression of this motif to disrupt MEKK2 dimer formation. Indeed, we found that expression of this motif led to a significant decrease in MEKK2 dimer formation in a dose-dependent manner (Fig.  3C) . Concomitantly, the interaction between the MEKK2 catalytic domain and this dimerization motif was increased.
Dimerization Leads to MEKK2 Activation through Transphosphorylation-Interestingly, although there are both phosphorylated and non-phosphorylated MEKK2 species in the cell lysates, we found that the non-phosphorylated MEKK2 (faster migrating band) was preferentially co-precipitated in the GST pull-down assay (Fig. 3A) . This suggested that the non-phosphorylated MEKK2 may form more stable dimers than the phosphorylated and, hence, activated MEKK2. To confirm this possibility, we used the same GST pull-down assay to assess the co-precipitation of untreated or protein phosphatase-treated MEKK2 or MEKK2-(342-619)(KM). As shown in Fig. 4A , only the non-phosphorylated species of MEKK2 was co-precipitated, suggesting that the non-phosphory-
FIG. 4. Nonphosphorylated MEKK2 forms dimers preferentially for MEKK2 transphosphorylation.
A, GST-MEKK2-(342-619) was co-transfected into COS-1 cells with expression vectors for HA-tagged MEKK2-(342-619) and MEKK2-(342-619)(KM), as indicated for a GST pull-down assay (top). Treatment with calf intestine phosphatase (CIP) was performed as described in the Fig. 1 legend. The total cell lysates were analyzed by immunoblotting with an anti-HA antibody (bottom). B, dimerization leads to MEKK2 autophosphorylation in a transphosphorylation manner. GST-MEKK2-(342-619) was co-transfected into COS-1 cells with an empty vector or expression vectors for HA-tagged MEKK2-(342-619) or MEKK2-(342-619)(KM), as indicated. The cell lysates were subjected to immunoprecipitation with an anti-HA antibody for an in vitro kinase assay (KA) (top). The total cell lysates were analyzed by immunoblotting with an anti-MEKK2 antibody (bottom). lated and inactive MEKK2 formed more stable dimers. This result also indicates that MEKK2 dimerization might occur prior to its phosphorylation and thus is required for activation.
To understand how MEKK2 dimerization leads to MEKK2 activation, we co-expressed a GST-MEKK2 fusion protein with either HA-MEKK2-(342-619) or HA-MEKK2-(342-619)(KM) proteins. The MEKK2 dimers were precipitated with an anti-HA antibody. After thorough washing, the immunocomplex was subjected to an in vitro kinase assay to determine the level of GST-MEKK2 phosphorylation. As shown in Fig. 4B , GST-MEKK2 precipitated by HA-MEKK2-(342-619) was phosphorylated. Consistently, HA-MEKK2 (342-619) was also phosphorylated in this complex. However, although a similar amount of full-length GST-MEKK2 was pulled down by HA-MEKK2-(342-619)(KM), neither GST-MEKK2 nor HA-MEKK2-(342-619)(KM) was phosphorylated in the same assay. This finding suggests that MEKK2 activation is mediated through transphosphorylation by two dimerized wild type catalytic domains.
Chemical-induced Dimerization in Vivo Activates the MEKK2-dependent MAPK Pathway-To test the dimerization dependence of MEKK2 activation in a more physiological setting, we utilized a well characterized chemically induced dimerization system to induce MEKK2 dimers in intact cells and determine whether this would activate MEKK2 and the MEKK2-dependent JNK-AP-1 pathway.
FKBP12 binds to the naturally occurring product FK506 and can be homodimerized with FK1012, which consists of two linked molecules of FK506 (31) . A synthetic, cell-permeable homodimerizing reagent, AP20187, which has a greatly reduced affinity for endogenous FKBP12 (ϳ250 nM), binds with high affinity (ϳ0.1 nM) to a F36V mutant (Fv) form of FKBP12 (32) . It was shown that the addition of low AP20187 concentrations to cells activated various proteins fused with the Fv domain with no adverse effect on the cells (26) . To adapt MEKK2 to chemical-induced dimerization control, we constructed expressing vector FvMEKK2CT by fusing the catalytic domain of MEKK2 with the Fv domain so that the fusion protein could be induced to form dimers in the presence of AP20187 as shown in Fig. 5A . We co-transfected the JNK expression vector with FvMEKK2CT and determined JNK activation in the absence or presence of AP20187. As shown in Fig. 5B , without cotransfection of FvMEKK2CT there was no JNK activation either in the absence or presence of AP20187, FIG. 5 . Dimerization is required MEKK2 activation. A, schematic drawing of chemically induced FvMEKK2CT dimerization by AP20187. B, MEKK2-dependent JNK activation is induced by AP20187. HA-JNK2 was cotransfected with an empty vector or with FvMEKK2CT or FvMEKK3CT as indicated. Thirty-six hours after transfection, cells were either untreated or treated with 20 nM AP20187 as indicated before being lysed for an in vitro kinase assay (KA) to phosphorylate GST-c-Jun (top). The expression levels of JNK2, FvMEKK2CT, and FvMEKK3CT were determined by immunoblotting (IB) with anti-HA antibody (bottom). C, MEKK2-dependent AP-1 reporter gene expression is induced by AP20187. A Gal4-luciferase reporter construct was co-transfected with an empty vector or with a Gal4-cJun expression vector alone or together with FvMEKK2CT. The Gal-Luc reporter activity was determined 36 h later. To induce MEKK2 dimer formation, AP20187 (20 nM) was added at 24 h after transfection, and cells were harvested at 36 h together with other samples. The Gal4-luc activity was normalized to ␤-actin-Renilla luciferase activity. D, disruption of MEKK2 dimers inhibits JNK activation by MEKK2. HA-tagged MEKK2-(342-619) and FLAG-tagged JNK1 were co-transfected into COS-1 cells with an increased amount of MEKK2-(342-424). JNK1 was immunoprecipitated for an in vitro kinase assay. The total cell lysates were analyzed by immunoblotting with anti-FLAG and anti-HA antibodies (middle and bottom).
suggesting that AP20187 has no effect on the basal activity of JNK. In contrast, co-transfection of FvMEKK2CT increased JNK activation in the absence of AP20187 as measured by its phosphorylation of GST-c-Jun. However, this low level JNK activation was greatly augmented by the addition of AP20187 (Fig. 5B) . Consistently, we observed a similar increase of the JNK/AP-1-dependent Gal4-c-Jun reporter gene expression by the addition of AP20187 (Fig. 5C) . Because of the high homology between the MEKK2 and MEKK3 catalytic domains, we expected that MEKK3 activation might also involve dimerization of its catalytic domain. To test this idea, we constructed an analogous FvMEKK3CT construct. Using the same assay, we demonstrated that dimerization of MEKK3 through its catalytic domain activated MEKK3 similarly to what we found with MEKK2 (Fig. 5, B and C) . Thus, these results provide in vivo evidence that MEKK2 dimerization leads to its activation.
If MEKK2 dimer formation is required for MEKK2 activation, we would expect that disrupting or blocking MEKK2 dimer formation should inhibit its activation of JNK. To test this notion, we expressed the MEKK2 dimerization motif MEKK2-(342-424) to disrupt MEKK2 dimers as shown in Fig.  3C and determined its effect on MEKK2-mediated JNK activation. As shown in Fig. 5D , we found that JNK activation by MEKK2 was significantly inhibited by the expression of the dimerization motif in a dose-dependent manner, further demonstrating that MEKK2 dimer formation is critical for MEKK2 signaling. DISCUSSION A key question regarding the specific activation of individual MAPK modules is how a MAP3K within a given MAPK module is first activated. Although there is ample evidence suggesting that MAP3Ks respond to numerous upstream stimuli, precisely how they are activated at the molecular level remains largely speculative. One of the major hurdles in studying MAP3Ks in mammalian systems is that, unlike MAP2Ks or MAPKs, once they are overexpressed most MAP3Ks become active, thus preventing further analysis of the mechanism of activation.
In this study, we investigated the underlying molecular mechanisms that govern the activation of MEKK2, a member of the MEKK/STE11 subgroup of MAP3K. The expression of MEKK2 by transient transfection revealed a phosphoprotein with a strong capacity for JNK activation. Removal of the phosphate by protein phosphatase treatment resulted in the loss of MEKK2 activity. We are in the process of identifying the active phosphorylation sites that are likely located within the activation loop of MEKK2 between the sub-kinase domains VII and VIII. Although it remains to be shown whether another kinase (MAP4K) is needed to phosphorylate the active sites in MEKK2, our current study suggests that MEKK2 is capable of self-phosphorylation and activation.
In this study, we found that MEKK2 is capable of forming dimers that lead to its self-phosphorylation and activation. We mapped the MEKK2 dimerization motif that is located within its catalytic domain and not in the NH 2 -terminal regulatory domain. Interestingly, activation of another MAP3K family member, Raf, also requires dimer formation (29, 33) . It was reported that the MAPK/RK2 also forms dimers through the catalytic domain (27) . Thus, it appears that dimerization may be an important regulatory mechanism for activation of certain Ser/Thr protein kinases. If our results are correct, we would expect that MEKK3 activation also involves dimer formation through its catalytic domain because there is high homology between MEKK2 and MEKK3 catalytic domains. Indeed, we found that MEKK3 also forms dimers through its catalytic domain and that induction of MEKK3 dimer formation in cells results in MEKK3-dependent JNK MAPK activation (Fig. 5,  B and C, and data not shown) .
It was recently reported that a putative protein-protein interaction motif called the PB-1 domain, located at the NH 2 -terminal region of MEKK2 and its homolog MEKK3, was involved in transducing activation signals to downstream MAPK modules (34 -36) . Although the PB-1 domain has the potential to form dimers, our study suggests that MEKK2 dimer formation does not depend on this domain. It is still possible that the PB-1 domain is involved only in the tethering of other regulatory proteins or MEKK2 substrates such as MEK5 (35) .
We used an induced dimerization system to show clearly that dimerization of MEKK2 could increase MEKK2 activity. However, it is unclear whether different MEKK2 stimuli all activate MEKK2 through this mechanism. If MEKK2 is capable of self-activation through dimer formation, how do cells prevent unwanted MEKK2 activation in the absence of stimulation when all of the cells seem to express endogenous MEKK2? One likely possibility is that there are putative proteins or factors in the cells to prevent the dimerization of MEKK2/3. An alternative mechanism is that MEKK2 or MEKK3 do not have a high affinity for each other unless they are modified (for instance by phosphorylation or ubiquitination) or tethered together by scaffold proteins following cell stimulation. Searching for proteins that are potential regulators of the MEKK2 signaling will provide further insight into the complex regulation of the MEKK2-dependent MAPK signal pathway.
